Hestia Palau S.L.
- Address
- Calle De San Antonio Maria Claret 135, 08025 Barcelona, Spain
Hestia Palau S.L. - Psychiatric Research Center
Hestia Palau S.L. is a specialized clinical research center dedicated to advancing the understanding and treatment of serious mental health disorders. The center demonstrates particular expertise in conducting complex psychiatric trials, focusing on novel therapeutic approaches for patients with Major Depressive Disorder (MDD) and schizophrenia, including those with treatment-resistant conditions and specific symptom profiles requiring adjunctive therapy strategies.
- Major Depressive Disorder with various presentations including moderate-to-severe anhedonia and insomnia symptoms
- Cognitive impairment associated with schizophrenia and long-term safety monitoring
- Novel pharmacological interventions as adjunctive therapies to standard antidepressants (SSRIs/SNRIs)
- Relapse prevention and maintenance treatment studies in psychiatric conditions
The center's research portfolio includes both short-term efficacy studies and long-term extension trials, demonstrating a commitment to comprehensive safety and tolerability assessments. Their experience spans multiple phases of clinical development, from Phase II efficacy trials to Phase III programs, with particular emphasis on evaluating innovative compounds such as aticaprant, seltorexant, iclepertin, NBI-1065845, and BH-200. The facility specializes in managing complex trial designs including double-blind, placebo-controlled studies with open-label extension phases for patients with inadequate response to current therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Neurocrine Biosciences Inc.2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hestia Palau S.L.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Aticaprant as Adjunctive Therapy in Adults with Major Depressive Disorder and Anhedonia Unresponsive to Antidepressants | Janssen Cilag International | Phase III | Not Recruiting | Nov 2024 | Feb 2025 |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE | 2 | Unknown | 2025-10-07 | 2025-10-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.